Medial Gastrocnemius Muscle Properties of Children With Cerebral Palsy After Different Tone Treatments: A Pilot Study

Am J Phys Med Rehabil. 2023 Oct 1;102(10):873-878. doi: 10.1097/PHM.0000000000002235. Epub 2023 Mar 8.

Abstract

Objective: Spasticity in children with cerebral palsy can be managed by a spectrum of approaches, from conservative therapy, to temporary botulinum toxin A injections, to permanent transection of sensory nerves with a selective dorsal rhizotomy. This pilot study investigated whether these three tone management approaches are associated with histological and biochemical properties of the medial gastrocnemius.

Design: A convenience sample of children with cerebral palsy undergoing gastrocnemius lengthening surgery was enrolled. Intraoperative biopsies were obtained from three individuals (one each: minimal tone treatment; frequent gastrocnemius botulinum toxin A injections; previous selective dorsal rhizotomy). All individuals had plantarflexor contractures, weakness, and impaired motor control before the biopsy.

Results: Differences between participants were observed for muscle fiber cross-sectional area, fiber type, lipid content, satellite cell density, and centrally located nuclei. The most pronounced difference was the abundance of centrally located nuclei in the botulinum toxin A participants (52%) compared with the others (3-5%). Capillary density, collagen area and content, and muscle protein content were similar across participants.

Conclusions: Several muscle properties seemed to deviate from reported norms, although age- and muscle-specific references are sparse. Prospective studies are necessary to distinguish cause and effect and to refine the risks and benefits of these treatment options.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Cerebral Palsy* / pathology
  • Child
  • Humans
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / etiology
  • Muscle, Skeletal / pathology
  • Neuromuscular Agents* / therapeutic use
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A
  • Neuromuscular Agents